The present results highlight gemigliptin add-on therapy as an effective treatment of choice compared with escalation of metformin dose in patients with inadequately controlled T2DM despite treatment with metformin and SGLT2 inhibitors, and no significant safety issues were noted. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.